Eleni Aklillu

8.9k total citations · 2 hit papers
174 papers, 6.3k citations indexed

About

Eleni Aklillu is a scholar working on Infectious Diseases, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Eleni Aklillu has authored 174 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Infectious Diseases, 60 papers in Pharmacology and 34 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Eleni Aklillu's work include Pharmacogenetics and Drug Metabolism (47 papers), HIV/AIDS drug development and treatment (39 papers) and Drug Transport and Resistance Mechanisms (30 papers). Eleni Aklillu is often cited by papers focused on Pharmacogenetics and Drug Metabolism (47 papers), HIV/AIDS drug development and treatment (39 papers) and Drug Transport and Resistance Mechanisms (30 papers). Eleni Aklillu collaborates with scholars based in Sweden, Ethiopia and Tanzania. Eleni Aklillu's co-authors include Leif Bertilsson, Magnus Ingelman‐Sundberg, Eyasu Makonnen, Omary Minzi, Roza Ghotbi, Sung Eun Sim, Getnet Yimer, Mette Krogh Christensen, Victor Næstholt Dahl and Carl Risinger and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Eleni Aklillu

167 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts

2021 673 citations Francine Ntoumi, Eleni Aklillu et al. International Journal of Infectious Diseases profile →
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

2006 562 citations Eleni Aklillu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eleni Aklillu Sweden	42	2.5k	1.8k	1.2k	949	922	174	6.3k
Zeruesenay Desta United States	45	4.0k 1.6×	1.2k 0.7×	2.4k 1.9×	947 1.0×	1.5k 1.6×	171	8.6k
Gerd Mikus Germany	53	2.4k 0.9×	1.3k 0.7×	1.4k 1.2×	1.5k 1.5×	1.0k 1.1×	254	7.9k
Kathrin Klein Germany	44	3.6k 1.4×	867 0.5×	2.9k 2.4×	1.3k 1.4×	1.8k 1.9×	112	7.7k
Jean‐Marc Tréluyer France	44	667 0.3×	1.8k 1.0×	1.2k 1.0×	1.8k 1.9×	806 0.9×	326	7.3k
Lars L. Gustafsson Sweden	49	1.7k 0.7×	627 0.3×	737 0.6×	1.5k 1.5×	551 0.6×	247	7.8k
Catia Marzolini Switzerland	36	712 0.3×	3.5k 1.9×	1.4k 1.1×	1.3k 1.4×	636 0.7×	130	6.0k
Laurent A. Décosterd Switzerland	50	768 0.3×	3.8k 2.1×	1.6k 1.3×	1.2k 1.3×	1.8k 2.0×	270	10.1k
Kenneth C. Lasseter United States	43	642 0.3×	1.1k 0.6×	825 0.7×	392 0.4×	978 1.1×	155	6.4k
Saı̈k Urien France	43	413 0.2×	995 0.6×	1.3k 1.1×	1.1k 1.2×	1.4k 1.6×	283	6.2k
Chantal Csajka Switzerland	36	460 0.2×	1.1k 0.6×	704 0.6×	596 0.6×	617 0.7×	165	4.4k

Countries citing papers authored by Eleni Aklillu

Since Specialization

Citations

This map shows the geographic impact of Eleni Aklillu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eleni Aklillu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eleni Aklillu more than expected).

Fields of papers citing papers by Eleni Aklillu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eleni Aklillu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eleni Aklillu. The network helps show where Eleni Aklillu may publish in the future.

Co-authorship network of co-authors of Eleni Aklillu

This figure shows the co-authorship network connecting the top 25 collaborators of Eleni Aklillu. A scholar is included among the top collaborators of Eleni Aklillu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eleni Aklillu. Eleni Aklillu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Petersen, Eskild, Seif Al-Abri, Ziad A. Memish, et al.. (2024). Screening for latent tuberculosis in migrants—status quo and future challenges. International Journal of Infectious Diseases. 141. 107002–107002. 6 indexed citations

Puijenbroek, Eugène van, Adam M. Fimbo, Omary Minzi, et al.. (2024). Short-Term Training, a Useful Approach for Sustainable Pharmacovigilance Knowledge Development in Tanzania, Kenya, Ethiopia and Rwanda. Drug Safety. 47(12). 1193–1202.

Mugusi, Sabina, et al.. (2024). CYP2B6 and ABCB1 genotypes predict methadone plasma exposure among patients on maintenance therapy against opioid addictions in Tanzania. British Journal of Clinical Pharmacology. 90(11). 2823–2836.

Minzi, Omary, et al.. (2024). Pharmacokinetics of piperaquine and its association with intermittent malaria preventive therapy outcomes during pregnancy. BMC Pharmacology and Toxicology. 25(1). 38–38. 2 indexed citations

Astatkie, Ayalew, et al.. (2023). Efficacy and safety of praziquantel treatment against Schistosoma mansoni infection among pre-school age children in southern Ethiopia. Tropical Medicine and Health. 51(1). 2 indexed citations

Mugisha, Michael, et al.. (2023). Efficacy of Single-Dose Albendazole for the Treatment of Soil-Transmitted Helminthic Infections among School Children in Rwanda—A Prospective Cohort Study. Pharmaceuticals. 16(2). 139–139. 6 indexed citations

Astatkie, Ayalew, et al.. (2023). Prevalence and Determinants of Schistosoma mansoni Infection among Pre-School Age Children in Southern Ethiopia. Pathogens. 12(7). 858–858. 4 indexed citations

Makonnen, Eyasu, et al.. (2023). Efficacy and safety of praziquantel preventive chemotherapy in Schistosoma mansoni infected school children in Southern Ethiopia: A prospective cohort study. Frontiers in Pharmacology. 14. 968106–968106. 9 indexed citations

Fimbo, Adam M., et al.. (2023). Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania. CPT Pharmacometrics & Systems Pharmacology. 12(12). 1884–1896. 3 indexed citations

10.

Tadesse, Birkneh Tilahun, et al.. (2023). Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia. CPT Pharmacometrics & Systems Pharmacology. 12(6). 783–794. 2 indexed citations

11.

Oluka, Margaret, et al.. (2023). Comparative Safety Surveillance of Triple (IDA) Versus Dual Therapy (DA) in Mass Drug Administration for Elimination of Lymphatic Filariasis in Kenya: A Cohort Event Monitoring Study. Drug Safety. 46(10). 961–974. 4 indexed citations

12.

Tefera, Gosaye Mekonen, et al.. (2022). Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review. Pharmacogenomics and Personalized Medicine. Volume 15. 561–571. 5 indexed citations

13.

Mugisha, Michael, et al.. (2022). Safety of Praziquantel and Albendazole Coadministration for the Control and Elimination of Schistosomiasis and Soil-Transmitted Helminths Among Children in Rwanda: An Active Surveillance Study. Drug Safety. 45(8). 909–922. 7 indexed citations

14.

Aklillu, Eleni, Workineh Shibeshi, Yumi Park, et al.. (2022). Population Pharmacokinetics of Levofloxacin and Moxifloxacin, and the Probability of Target Attainment in Ethiopian Patients with Multidrug-Resistant Tuberculosis. Infection and Drug Resistance. Volume 15. 6839–6852. 3 indexed citations

15.

Matendechero, Sultani, et al.. (2021). Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study. Pharmaceuticals. 14(3). 264–264. 8 indexed citations

16.

Kilonzi, Manase, Omary Minzi, Ritah Mutagonda, et al.. (2020). Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania. Malaria Journal. 19(1). 66–66. 3 indexed citations

17.

Thulin, Petra, Gunnar Nordahl, Marcus Gry, et al.. (2013). Keratin‐18 and micro RNA ‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts. Liver International. 34(3). 367–378. 89 indexed citations

18.

Aklillu, Eleni, Linda Odenthal-Hesse, Abiy Habtewold, et al.. (2013). CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans. BMC Infectious Diseases. 13(1). 536–536. 15 indexed citations

19.

Yimer, Getnet, Nobuhisa Ueda, Abiy Habtewold, et al.. (2011). Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients. PLoS ONE. 6(12). e27810–e27810. 84 indexed citations

20.

Habtewold, Abiy, Wondwossen Amogne, Eyasu Makonnen, et al.. (2011). Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. Journal of Antimicrobial Chemotherapy. 66(10). 2350–2361. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact